5300 Memorial Drive
Suite 950
Houston, TX 77007
United States
713 300 5160
https://www.moleculin.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 18
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Walter V. Klemp | Founder, Chairman, President & CEO | 894.54k | N/D | 1960 |
Mr. Jonathan P. Foster CPA | Executive VP & CFO | 611.17k | N/D | 1964 |
Dr. Donald H. Picker Ph.D. | Chief Scientific Officer | 486.44k | N/D | 1946 |
Dr. Waldemar Priebe Ph.D. | Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board | N/D | N/D | N/D |
Dr. Robert C. Shepard FACP, M.D. | Chief Medical Officer of Annamycin | N/D | N/D | 1952 |
Dr. John Paul Waymack M.D., Sc.D. | Senior Chief Medical Officer | N/D | N/D | 1952 |
Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer of New Products | N/D | N/D | 1955 |
Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D. | European Chief Medical Officer | N/D | N/D | N/D |
Ms. Jacqueline Northcut | Consultant | 51.11k | N/D | 1962 |
Mr. Louis Ploth Jr. | Independent Advisor | 118.49k | N/D | 1954 |
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.
La calificación ISS Governance QuickScore de Moleculin Biotech, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.